Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Annelise Capossela/Axios

Facebook said Wednesday it's seeing signs that resistance to the COVID-19 vaccine is weakening both in the United States and abroad, though it acknowledged it still doesn't have hard numbers on how frequently misinformation is being shared on its platforms.

Why it matters: Facebook touts a survey showing improved attitudes toward the vaccines, but that survey finding raises questions, as other polling has shown significant and entrenched hesitancy, especially in the U.S. It also doesn't show that Facebook or other social media can be credited for any shift.

When it comes to the spread of hate speech, child exploitation and other types of problematic content, Facebook says the key metric is prevalence — that is, how often such content is shown — and points to declines in such information appearing on its site. Hate speech, for example, represents just five posts in 10,000.

  • But Facebook said it doesn't yet have data to share when it comes to COVID-19 misinformation.
  • Instead, Facebook points to other statistics, such as how many times people viewed authoritative content about the vaccine, or how many users posted a profile picture frame highlighting their vaccination status.
  • The company acknowledged that anti-vaccine information is often less overt than changing a profile picture.

The other side: Critics blasted Facebook, with Accountable Tech executive director Nicole Gill saying that "Facebook is teeming with deadly vaccine misinformation."

  • "It is hard to overstate the shamelessness of Facebook executives who continue to portray the company as heroes of this pandemic and dutiful custodians of authoritative information," Gill said in a statement.
  • "You don’t have to take my word for it – just spend a few hours on the platform," Gill said. "Or listen to the heartbreaking testimonials from health workers who have lamented their dying patients’ exposure to those viral lies."
  • The Biden Administration also criticized Facebook. “In the middle of a pandemic, being honest and transparent about the work that needs to be done to protect public health is absolutely vital, but Facebook still refuses to be straightforward about how much misinformation is circulating – and being actively promoted – on their platform," White House spokesman Michael Gwin said in a statement to Axios.

Facebook also released for the first time a report on the most widely viewed content, including specific links and domains, aiming to show that such content is a mix that includes memes and nonprofit organizations.

  • The New York Times' Kevin Roose has used Facebook's CrowdTangle data to show that the content that is most widely engaged with tends to be right-leaning political content.
  • Facebook's new data doesn't contradict these findings, but offers up a different metric.
  • "The narrative that has emerged is quite frankly wrong," Guy Rosen, Facebook's vice president of Integrity, said on a conference call with reporters. "We think it is really important for this data to be out there."

The big picture: Facebook has long argued that engagement as a proxy alone shouldn’t be used to determine what’s the most vital content in its platform. Instead, it’s argued that reach is a better metric.

  • But the tech giant for years has refused to release reach data, frustrating journalists that rely on engagement data from CrowdTangle.

Between the lines: Earlier this summer, the New York Times published a report that said Facebook was moving CrowdTangle over to its community standards enforcement team, to help it better identify threats.

  • Sources say this caused frustration among CrowdTangle employees, who worried about whether the data would still be visible enough to the public.
  • Facebook is now releasing reach data, but on its own terms. 
  • The lists don’t show what’s garnering the most reach at any given time, like CrowdTangle does, but rather over larger chunks of time, to show generalized patterns.

Go deeper

Sep 17, 2021 - Health

FDA advisory panel recommends Pfizer boosters for those 65 and older

A healthcare worker prepares a dose of the Pfizer-BioNTech Covid-19 vaccine at the Key Biscayne Community Center on Aug. 24, 2021. Photo: Eva Marie Uzcategui/Bloomberg via Getty Images

A key Food and Drug Administration advisory panel on Friday overwhelmingly voted against recommending Pfizer vaccine booster shots for younger Americans, but unanimously recommended approving the third shots for individuals 65 and older, as well as those at high-risk of severe COVID-19.

Why it matters: While the votes are non-binding, and the FDA must still make a final decision, Friday's move pours cold water on the Biden administration's plan to begin administering boosters to most individuals who received the Pfizer vaccine later this month.

Tina Reed, author of Vitals
Sep 17, 2021 - Health

Key FDA committee takes on the big booster question

Illustration: Sarah Grillo/Axios

A key FDA advisory committee is meeting today to discuss Pfizer's proposal for a COVID vaccine booster — but it will set the stage for the entire booster debate.

The big question: Not only whether experts believe there’s enough evidence to support boosters, but also whether they believe additional shots should be made available for everyone or limited to older Americans and the immunocompromised.

Updated Sep 17, 2021 - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Vaccines: Key FDA committee takes on the big booster question — Los Angeles County to require vaccination proof at indoor bars — France suspends 3,000 unvaccinated health workers without pay.
  2. Health: Worsening crisis at Rikers Island jail spurs call for action — 1 in 500 Americans has died — Cases are falling, but deaths are rising.
  3. Politics: White House invites call with Nicki Minaj to discuss vaccine — Gottlieb says CDC hampered U.S. response — 26 states have limited state or local officials' public health powers.
  4. Education: Denver looks to students to close Latino vaccination gap — Federal judge temporarily blocks Iowa's ban on mask mandates in schools — Massachusetts activates National Guard to help with school transportation.
  5. Variant tracker: Where different strains are spreading.